« Previous
Next »
Titles
- Biologics in perspective: the case for generic biologic drugs1
- Competitive bidding in drug procurement: evidence from China1
- Drug discount program: federal oversight of compliance at 340B contract pharmacies needs improvement : report to Congressional requesters1
- Drug discount program: improvements needed in federal oversight of compliance at 340B contract pharmacies : testimony before the Subcommittee on Health, Committee on Energy and Commerce, House of Representatives1
- Drug discount program: status of agency efforts to improve 340B program oversight : testimony before the Committee on Health, Education, Labor, and Pensions, U.S. Senate1
- Drug price moderation in Germany: lessons for U.S. reform efforts1
- Equilibrium effects of pharmaceutical bundling: evidence from India1
- Indication-specific pricing of pharmaceuticals in the United States health care system: a report from the 2015 ICER Membership Policy Summit1
- Medicare Part B drug payments: impact of price substitutions based on 2017 average sales prices1
- Medicare Part D1
- The Medicaid Drug Rebate Program: the basics1
- The effect of Medicare Part D on evergreening, generic entry, and drug prices1
- What's the latest on Medicare drug price negotiations?1